FDA accelerates review of Novartis’s Zykadia for first-line treatment in lung cancer
Swiss pharma Novartis has announced that its lung cancer drug Zykadia (ceritinib) has been granted the FDA priority review for its expanded use as the first-line treatment for lung cancer patients with certain conditions.
Novartis AG, a prominent Swiss pharmaceutical company, has received a significant regulatory boost as its lung cancer medication, Zykadia (ceritinib), has been granted a priority review by the U.S. Food and Drug Administration (FDA) for its expanded use in treating lung cancer. This priority review specifically targets its application as a first-line treatment for patients […]